MALVERN, PA February 3, 2016 Galera Therapeutics, Inc., a clinical-stage biotech developing new treatments for cancer patients, announced today it has received an additional $5 million in funding from Enso Ventures to bring its Series B financing total to $42 million. Enso Ventures joins existing investors New Enterprise Associates, Novartis Venture Fund, Novo Ventures, Correlation Ventures and Galera Angels.

View full article here.